Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GBSNASDAQ:ICADNASDAQ:LUNGNASDAQ:MGRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBSGBS$1.78-2.7%$1.53$0.36▼$2.89$26.50M1.32955,325 shs508,618 shsICADicad$3.69-0.5%$3.75$1.19▼$4.02$101.37M1.37419,429 shs107,801 shsLUNGPulmonx$2.78+5.3%$3.18$2.50▼$9.37$111.92M0.45304,617 shs134,545 shsMGRMMonogram Orthopaedics$3.25+11.7%$2.72$1.92▼$4.21$115.99M0.59248,965 shs163,682 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBSGBS0.00%+16.34%+7.23%+34.85%-2.73%ICADicad-1.46%-2.62%-4.87%+123.49%+209.17%LUNGPulmonx-4.86%+1.93%-16.72%-53.85%-59.32%MGRMMonogram Orthopaedics0.00%+0.69%+14.57%+21.76%+39.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGBSGBSN/AN/AN/AN/AN/AN/AN/AN/AICADicad0.639 of 5 stars0.05.00.00.01.30.80.0LUNGPulmonx3.0025 of 5 stars3.33.00.00.02.03.30.6MGRMMonogram Orthopaedics2.323 of 5 stars3.82.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBSGBS 0.00N/AN/AN/AICADicad 2.00HoldN/AN/ALUNGPulmonx 2.63Moderate Buy$11.53314.57% UpsideMGRMMonogram Orthopaedics 3.50Strong Buy$5.4066.15% UpsideCurrent Analyst Ratings BreakdownLatest GBS, LUNG, ICAD, and MGRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/17/2025ICADicadLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/16/2025ICADicadBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/16/2025ICADicadCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBSGBSN/AN/AN/AN/A$0.44 per shareN/AICADicad$19.53M5.19N/AN/A$1.08 per share3.42LUNGPulmonx$83.79M1.34N/AN/A$2.17 per share1.28MGRMMonogram OrthopaedicsN/AN/AN/AN/A$0.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/AICADicad-$5.62M-$0.19N/A∞N/A-26.63%-15.03%-11.77%8/12/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)MGRMMonogram Orthopaedics-$16.33M-$0.45N/AN/AN/AN/A-115.71%-92.75%8/13/2025 (Estimated)Latest GBS, LUNG, ICAD, and MGRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025LUNGPulmonx-$0.40N/AN/AN/A$23.46 millionN/A5/14/2025Q1 2025MGRMMonogram Orthopaedics-$0.12-$0.10+$0.02-$0.10N/AN/A5/13/2025Q1 2025ICADicad-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBSGBSN/AN/AN/AN/AN/AICADicadN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBSGBSN/A2.332.33ICADicadN/A3.663.57LUNGPulmonx0.384.974.29MGRMMonogram OrthopaedicsN/A7.007.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBSGBS2.79%ICADicad24.61%LUNGPulmonx91.04%MGRMMonogram Orthopaedics0.45%Insider OwnershipCompanyInsider OwnershipGBSGBS0.27%ICADicad10.29%LUNGPulmonx6.80%MGRMMonogram Orthopaedics28.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBSGBS714.89 million14.85 millionNot OptionableICADicad14027.47 million24.64 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableMGRMMonogram Orthopaedics2835.69 million25.66 millionNot OptionableGBS, LUNG, ICAD, and MGRM HeadlinesRecent News About These CompaniesMonogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred StockJuly 8 at 8:30 AM | accessnewswire.comAEarnings call transcript: Monogram Orthopaedics sees stock surge after Q1 2025 resultsMay 16, 2025 | investing.comMonogram Technologies Inc. (MGRM) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comMonogram Orthopaedics, Inc. (NASDAQ:MGRM) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comA Look Ahead: Monogram Technologies's Earnings ForecastMay 15, 2025 | benzinga.comMonogram Technologies Inc.: Monogram Technologies Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deMonogram Tech Gets FDA Clearance for Total Knee Arthroplasty SystemMay 15, 2025 | marketwatch.comMonogram Technologies Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comMonogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern TimeMay 6, 2025 | accessnewswire.comACORRECTION FROM SOURCE: Monogram Technologies Receives Regulatory Approval to Start Clinical Trials in IndiaApril 29, 2025 | accessnewswire.comAMonogram Technologies Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation in IndiaApril 29, 2025 | accessnewswire.comAMonogram Orthopaedics Inc (MGRM) Receives a Rating Update from a Top AnalystApril 16, 2025 | markets.businessinsider.comWhy Monogram Technologies Inc.’s (MGRM) Stock Is Down 10.69%March 25, 2025 | aaii.comAMGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System.March 20, 2025 | msn.comMonogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder CommunityMarch 20, 2025 | accessnewswire.comAMonogram Orthopaedics price target raised to $5.40 from $4 at Roth MKMMarch 18, 2025 | markets.businessinsider.comMonogram Orthopaedics announces 510(k) clearance for mBos TKA SystemMarch 17, 2025 | markets.businessinsider.comFDA clears robotic knee surgery system from Monogram TechnologiesMarch 17, 2025 | massdevice.comMonogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA SystemMarch 17, 2025 | accessnewswire.comAAnalysts Offer Insights on Healthcare Companies: Monogram Orthopaedics Inc (MGRM) and Vivani Medical (VANI)March 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseSouthwest Airlines: Short Interest Plunges—Should You Buy?By Gabriel Osorio-Mazilli | June 17, 2025View Southwest Airlines: Short Interest Plunges—Should You Buy?GBS, LUNG, ICAD, and MGRM Company DescriptionsGBS NYSE:GBS$1.78 -0.05 (-2.73%) As of 07/3/2025GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.icad NASDAQ:ICAD$3.69 -0.02 (-0.54%) As of 03:15 PM EasterniCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.Pulmonx NASDAQ:LUNG$2.78 +0.14 (+5.30%) As of 03:15 PM EasternPulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Monogram Orthopaedics NASDAQ:MGRM$3.25 +0.34 (+11.68%) As of 03:10 PM EasternMonogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
